B+
Bull case
25%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
TYRA
Tyra BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+65.5
Score
AI commentary
The post-earnings update is mixed: the September SURF302 readout remains intact and cash runway is strong, but BEACH301 data moved to end-Q1 2027 [#SEC-8K-2026-08-04]. Social coverage is unavailable, and analyst revision or consensus-surprise data are unavailable; missing reaction data is not positive evidence. This remains a cautious monitoring view ahead of SURF302.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventSURF302 initial Phase 2 readout expected in September 2026High impact
Tyra expects initial safety results from more than 40 patients and efficacy results from more than 20 patients in the SURF302 study, making this the clearest near-term binary valuation test [#SEC-8K-2026-08-04].
2027-03-31catalystBEACH301 readout delayed to end-Q1 2027High impact
The safety-sentinel readout moved from Q4 2026 to end-Q1 2027 after opening a fifth dose level, reducing near-term catalyst density and potentially weighing on sentiment [#SEC-8K-2026-08-04].
2027-12-31catalystSURF303 remains a 2027 development milestoneHigh impact
The Phase 2a/b LG-UTUC program has begun dosing and could support a future NDA pathway, but efficacy remains unproven and initial results are not expected until 2027 [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology